Research programme: IDO1 inhibitors - Netherlands Translational Research Center
Latest Information Update: 28 Aug 2020
At a glance
- Originator Netherlands Translational Research Center
- Class Antineoplastics
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Cancer in Netherlands
- 27 Jul 2016 Early research in Cancer in Netherlands (unspecified route)